secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vor Biopharma Inc. (VOR)
CIK:        0001817229
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001193125-26-127609
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vor Biopharma raises $75M via private placement with TCGX for telitacicept development
--------------------------------------------------------------------------------

- Gross proceeds of $75M from sale of 5.34M shares at $14.05/share to TCGX affiliates.
- Closing expected March 30, 2026; no placement agent used.
- Proceeds to advance Phase 3 trials for myasthenia gravis and primary Sjögren's disease.
- TCGX managing partner expresses confidence in telitacicept's differentiated profile.
- Registration rights agreement to file resale registration statement within 30 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817229/000119312526127609/0001193125-26-127609-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817229/000119312526127609/vor-20260326.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-127609

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer